Evidence map›Paper›PMID 37160416›Full record

ArticleThoracic cancer2023

Genomic profile of Pancoast syndrome due to hepatocellular carcinoma: A case report.

Drew T Bergman, Lorraine Zaki, Jason R Pettus, Bassem I Zaki, Manik Amin

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Pancoast Syndrome Due to Metastatic Hepatocellular Carcinoma.Journal of Brown hospital medicine · 2024
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Drew T BergmanGeisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.ORCID 0000-0002-8314-7088
Lorraine ZakiUniversity of Rochester, Rochester, New York, USA.
Jason R PettusPathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Bassem I ZakiRadiation Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Manik AminHematology/Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Dartmouth–Hitchcock Medical Center · USDartmouth College · USUniversity of Rochester · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a common cancer and is frequently diagnosed at a late and unresectable stage with limited effective treatment options. Here, we present the fifth reported case of a 77 year-old male with metastatic HCC presenting as a symptomatic superior sulcus lung tumor and discuss the genomic profile of this rare presentation of HCC for the first time, which included multiple classic mutations in HCC such as TERT, TP53, and WNT/β-catenin signaling as well as in the DNA repair gene ATM. The patient was treated with palliative radiotherapy to the Pancoast tumor followed by atezolizumab plus bevacizumab and passed away 6 months after diagnosis. This rare case highlights the need for effective treatment in aggressive and unresectable HCC and the utility of early genomic studies to allow for targeted therapy such as poly (ADP-ribose) polymerase (PARP)-inhibitors.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsPancoast SyndromeAgedGenomicsHumansMaleTreatment Outcomehepatocellular carcinomaimmunotherapypalliative radiationPancoast tumorsuperior sulcus tumor

Identifiers

PMID37160416
PMCPMC10290913
OpenAlexW4376121449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.